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Overactive Bladder Syndrome (OAB) represents a health condition of increasing 
public and medical recognition. The burden on the individual patient and the potential 
economic impact is staggering. 
Public Health care in SA is economically under resourced. Treatment modalities for 
OAB in these settings are limited to bladder training and oral immediate-release 
oxybutynin. Long term effectiveness and tolerance is unsatisfactory in some patients. 
There is currently no alternative therapy available to them. 
  
Objectives 
To evaluate the efficacy of acupuncture in refractive OAB. The primary aim was to 
evaluate the effect on frequency, nocturia and urge urinary incontinence.  The 
secondary aim was to evaluate the effect of the response on self-perceived quality-of-
life. 
 
Patients and methods 
The study was conducted at a specialized urogynaecology unit in a resource limited 
setting. In a self-controlled time cohort study, 20 consecutive women with OAB who 
were refractive to standard treatment, were recruited. Participants received weekly 
acupuncture treatments for four weeks. Three-day bladder diaries and the King’s 
Health Questionnaire (KHQ) were completed at 3 intervals: at baseline; at week 6; 
and at 3 months.  
  
Results 
There was a 22% (p=0.002) and 23% (p=0.002) decrease in frequency, a 38% 
(p=0.004) and a 31% (p=0.015) decrease in nocturia and a 20% (p=0.002) and a 32% 
(p=0.0003) decrease in incontinence from baseline to week 6 and to 3 months 
respectively.  
Both the general domains of the KHQ showed significant improvement by 3 months 
(P=0.002 and 0.009 respectively). 
All seven lifestyle domains showed significant improvement at week 6 and again at 3 














The only domain that showed a marginal significant decrease from week 6 to 3 
months was Social Limitation (p=0.49). 
  
Conclusion 
In this study of women with refractive OAB, acupuncture produced significant 





































OAB   Overactive Bladder Syndrome 
ICS   International Continence Society 
UI   Urinary Incontinence 
UUI   Urgency Urinary Incontinence 
SUI   Stress Urinary Incontinence 
BMI  Body Mass Index 
QoL  quality-of-life 
FCC  Female Continence Clinic 
GSH  Groote Schuur Hospital 
frequency  refers to urinary frequency 
urgency  refers to urinary urgency 
HRT  Hormone replacement therapy 


































Overactive Bladder Syndrome (OAB) represents a health condition of increasing 
public and medical recognition. Current treatment options for patients who are 
diagnosed with OAB in resource limited settings in South Africa are limited to 
bladder retraining and oxybutynin. Our anecdotal experience at a specialised 
urogynaecological unit is that these modalities are often associated with unsatisfactory 
cure rates. A recent retrospective chart based audit on 84 patients with urgency 
urinary incontinence (UUI) attending the Female Continence Clinic at Groote Schuur 
Hospital in Cape Town found that only 23% considered their symptoms to have 
improved with the standard treatment (1). We have no further therapy to offer these 
patients.  
 
When considering its distressing impact, it is not difficult to appreciate that these 
troublesome symptoms may represent a continuous, daily burden on any individual's 
functioning. There is a growing demand for OAB research to provide physicians with 
new treatment modalities to improve the quality of care in patients with this disorder. 
 
Acupuncture for bladder dysfunction has been used in traditional Chinese medicine 
for many years. Recent scientific studies have shed some light on the possible 
mechanism of this intervention. This has subsequently led to acupuncture trials for 
OAB with noticeable results. Acupuncture is safe and well tolerated with few side 
effects. Considering that there is no alternative treatment available in our unit, 
acupuncture for patients with refractive OAB was investigated. 
 
1.2    Terminology 
 
The overactive bladder was identified as a condition by the International Continence 
Society (ICS) in 1988 when it was introduced, as a diagnostic entity, to incorporate a 














urgency, and nocturia (2). The exact definition has been a point of debate for several 
years.  
 
To enable better communication and understanding among clinicians, researchers and 
the public, the ICS adopted broader, symptom-based definition in 2001 by 
encompassing a “syndrome of symptoms”. This consensus definition defines OAB as 
urinary urgency, with or without urge incontinence, usually with urinary frequency 
and nocturia, in the absence of pathologic or metabolic factors that would explain 
these symptoms (3). 
 
Urgency has now become the cornerstone symptom of OAB (4). It is defined as the 
complaint of a sudden compelling desire to pass urine, which is difficult to defer. 
Urge urinary incontinence (UUI), also referred to as “OAB-wet”, is the complaint of 
involuntary leakage accompanied by or immediately preceded by urgency. A patient 
who considers that he/she voids too often by day has increased daytime frequency and 
nocturia is the complaint that the individual has to wake at night more than once to 
void. These ICS-definitions adequately described bladder symptoms within the OAB 
population when assessed by the level of symptom bother (5). 
 
A subset of patients with overactive bladder symptoms experience urgency, 
frequency, and nocturia, but do not have urge incontinence, a condition referred to as 
"OAB-dry." 
 
For the purpose of this study, refractive OAB was defined by symptoms not 
satisfactorily relieved by standard first-line treatment given at our specialised unit.  
 
1.3    Prevalence of OAB in women 
 
Until recently, prevalence data for OAB were lacking.  Differences in definition and 
assessment of symptoms made it difficult to compare data across studies. The new 
definition proposed by the ICS attempted to eliminate this problem by standardising 
terminology. Since then, the definitions have been accepted internationally and study 
















The methodology used for collecting data can also make comparison challenging. 
Some data is collected using postal questionnaires while other investigators conduct 
personal or telephonic interviews. In instances where postal surveys are used, varying 
response rates may introduce bias to the data. Incontinent women may ignore 
questionnaires, deny having UI or they may respond in greater numbers because they 
are drawn to the subject.  Interview responses on the other hand may be more 
susceptible to social bias. 
 
Crude prevalence studies from the United States and Europe are abundant, but these 
population surveys focused on UI in general. Three recent surveys represent a 
significant advance in our understanding of the prevalence of specifically OAB 
symptoms and their impact. This data, from the United States and Europe, has 
confirmed the clinical suspicion that OAB is a highly prevalent disorder. 
. 
Two of the three large population-based studies have been conducted before the new 
definition of OAB was introduced. 
 
In the European survey of 16 776 men and women aged 40 years and older, Milsom et 
al. (6) reported OAB symptoms in 16.6% of respondents. This survey was conducted 
by telephone interviews and, in Spain, by face-to-face interviews (due to the lower 
proportion of households having a telephone). Frequency (85%) was the most 
commonly reported symptom, followed by urgency (54%) and urge incontinence 
(36%). Of these patients, 79% had experienced symptoms for at least a year with 49% 
experiencing symptoms for more than three years.  By extrapolating the results, the 
investigators estimated that a total of 22.18 million individuals in France, Italy, Spain, 
Sweden, Germany and the United Kingdom are burdened by OAB.  
 
A similar prevalence was found in the USA. The National Overactive Bladder 
Evaluation Program (7) surveyed over 17,000 households using a clinically validated 
computer-assisted telephone interview questionnaire.  This survey was validated and 
had a sensitivity of 61% and specificity of 91% for OAB. Of the women who were 














were incontinent.  Applied to the US population as a whole, this translates into 
approximately 33.3 million affected adults. 
 
The third study, known as the EPIC study (8), is the largest multinational, population 
based, cross-sectional survey to estimate the prevalence of lower urinary tract 
symptoms using current ICS definitions. A total of 58 139 adults aged 18 years or 
older were contacted in Canada, Germany, Italy, Sweden and the UK and 19 165 
participated in the survey. The prevalence of OAB in women was 12.8%.  
 
The geographical diversity of these surveys calls into question whether the population 
surveyed significantly impacts on the reported prevalence of OAB. There is no 
epidemiological evidence to support a difference in prevalence rates between 
countries. A slightly higher prevalence was reported in Spain in Milson’s survey. This 
may reflect the method of data collection. The survey was conducted by direct 
interview in which respondents may have felt more able to discuss their bladder 
control problems.  
 
The prevalence rate in developed areas seems to correlate with the limited data 
available on those in developing areas. In Korea, for example, the prevalence of OAB 
was 14.3% (9). 
 
There is, however, very little data available on the epidemiology of urinary 
incontinence on the African continent. A Medline search using keywords 
“incontinence”, “Africa” followed by a sequential Medline search using 
“incontinence” and each of the 56 African countries revealed scanty data on 
incontinence overall with only a handful of poor quality studies reporting basic 
epidemiological data such as prevalence. None of these studies were conducted in 
South Africa. 
 
Africa has unique problems and challenges. We suspect that women in Africa believe 
that there is no effective treatment for incontinence available and might see 
incontinence as a normal process of aging. Racial and cultural differences in help-














bladder control. For long it has been suspected that black South African women rarely 
develop stress incontinence (10), but little is known regarding urge incontinence. 
 
1.4    Incidence and Natural History of OAB in women 
 
Despite recent advances in the standardisation of definitions and diagnostic criteria 
for OAB and the understanding of the epidemiology and risk factors, very few studies 
have reported on the incidence and natural history of OAB.  
 
An important prospective study by Wennberg et al. (11) looked at the progression of 
OAB in the same women over 16 years. Frequency increased by 3% (P<0.001) and 
nocturia by 20% (P<0.05) from 1991 to 2007. The incidence of OAB was 20% and 
the corresponding remission rate was 43%. A limitation to this study is that it is not 
clear whether the level of remission reflects active treatment or whether it is part of 
the natural course of incontinence. 
 
In 2009 Garnett et al. (12) assessed the long-term natural history of OAB symptoms. 
In their study they reviewed the original urodynamic traces of women who were 
referred to a urogynaecological  unit with OAB symptoms at least 10 years earlier. All 
patients with a confirmed diagnosis of OAB were offered a repeat urodynamic and 
symptomatic assessment. OAB symptoms were persistent in 88% of the study 
population. Similarly Aitchison et al. (13) reported 88% of patients with urge 
incontinence to be unchanged at 5-year follow-up. 
 
Nygaard et al. (14) interviewed and then re-interviewed 2025 women older than 65 
years at three and 6-year intervals. The incidence and remission rates for OAB-wet 
without treatment intervention were 29% and 22% respectively.  
 
OAB seems to be a dynamic condition and it is highly likely that symptoms continue 
in the long term. 
 
1.5    Risk Factors for OAB in women 
















OAB is likely to become a more significant clinical problem with age. In the 
EPINCONT study (15), a large Norwegian survey of over 27 000 people, the risk 
factors for UI were analysed separately in strata of different types. They found that 
the lowest prevalence was observed in the younger age groups (12% for women <30 
years), the highest was observed among the eldest (40% for women >90 years). 
However, there was also a peak around mid-age with a prevalence of 30% among 
women 50–54 years of age. Epidemiological studies have implicated oestrogen 
deficiency in the aetiology of lower urinary tract symptoms occurring following the 
menopause. Estrogen and progesterone receptors have been found throughout the 
lower urinary tract (16), and many of the tissues involved in female continence have 
been found to be oestrogen-sensitive. Urge urinary incontinence is more prevalent 
after the menopause (17). The peak prevalence of stress urinary incontinence occurs 
around the time of the menopause but declines following the menopause (18) . 
Seventy percent of incontinent postmenopausal women relate the onset of their 
incontinence to the time of their menopause (19). 
 
In the NOBLE study (7), the likelihood of OAB-wet increased markedly between the 
ages of 35 and 44 years, with a further increase after age 55 years. Although older age 
seems to be associated with OAB, it is not only the elderly who suffer from it. It is 
well documented that the OAB-prevalence is also significant in a younger population. 
In the EPIC study (8), 43% of respondents were aged 40–64 years. Van der Vaart et 
al. (20) reported a prevalence of 11.9% for OAB-dry and 15.3% for OAB-wet in a 
female population aged 20-45 years. 
 
Most studies have shown obesity to be commonly associated with incontinence and 
the prevalence of OAB-wet is seen to increase with an increasing body mass index 
(BMI). In the NOBLE study (7), the prevalence of OAB-wet in participants with a 
BMI more than 30 was 2.2 times higher than those among participants with BMI's 
less than 24. Liberman et al. (21) found that 42.1% of respondents who experienced 
incontinence were in the top third of the BMI range. In the Heart and 
Estrogen/Progestin Replacement Study (HERS) (22), increasing BMI was found to be 
a significant predictor of incontinence. This study published an evaluation of the 














secondary endpoint in this cardiac prevention trial. Self-reported incontinence was 
documented at 4 months after randomization and then yearly over the study period. 
During the 4 years of treatment, 64% of the women randomly assigned to hormone 
therapy compared with 49% of those assigned to placebo reported weekly 
incontinence. This higher risk was evident at 4 months and persisted throughout 
treatment. This effect appears to be independent of age. Four years of treatment with 
HRT caused an excess risk of 12% for weekly urge incontinence episodes and 16% 
for weekly stress incontinence. It was suggested by the authors that the association of 
hormone therapy and incontinence might be due to the progestogen component of this 
regimen. 
 
Between 1993 and 1998, the Women’s Health Initiative (WHI) study group 
performed a multicenter, double-blind, randomized trial of menopausal women. In 23 
296 study subjects aged between 50 and 79 years, urinary symptoms were reviewed at 
baseline and after 1 year (23). The incidence of urinary symptoms was reported via a 
standardized and validated questionnaire. Measurements of severity included self-
reported frequency, and associated limitations in daily activities and ‘degree of 
bother’. Women were randomly assigned to receive either HRT or placebo.  For those 
who reported no urinary symptoms at baseline, combined HRT was associated with 
an increased incidence of any urinary incontinence at 1 year. For those women who 
had initially reported urinary incontinence upon enrolment, there was a significant 
increase in the risk of worsening symptoms in the combined HRT group. Of those 
who had reported some degree of urinary incontinence at baseline, there was also a 
significant risk of worsened symptoms with oestrogen treatment. The HERS and WHI 
trial were primarily designed to evaluate other outcomes. The urinary tract measures 
were limited to self-reported, subjective descriptions of incontinence symptoms 
without more reproducible, objective outcomes. However, self-reported symptoms are 
important in reflecting the experience of patients and are useful in assessing the 
overall benefits of such a treatment. 
 
During the 1990s, the Hormones and Urogenital Therapy (HUT) Committee produced 
a meta-analysis report to clarify the confusion over oestrogen use for the treatment of 
urinary symptoms (24). On identifying 166 articles, 23 met the entry criteria. Of 














found an overall significant beneficial effect of oestrogen on subjective symptom 
improvement for all subjects and for subjects with urodynamic stress incontinence 
alone. Placebo groups also reported subjective improvement of 10–56%. There were, 
however, no objective data and the studies included heterogeneous groups and 
considerably varying diagnostic criteria, therapeutic interventions and outcome 
assessments. 
 
In a case-control study by Parazzini (25), over a 1000 women with OAB were 
consecutively observed in first level gynaecological centres in Italy. They found an 
increased risk of all types of urinary incontinence in women who had undergone 
hysterectomies, but they did not find any association among vaginal delivery, 
menopausal status, age at menopause and risk of urinary incontinence. In the HERS 
hormone replacement did not affect the frequency of SUI or UUI. 
 
Data from the EPINCONT study (26) further demonstrated that former and current 
smoking was associated with incontinence, but only for those who smoked more than 
20 cigarettes per day. Severe incontinence was weakly associated with smoking 
regardless of number of cigarettes. 
 
1.6    The Impact of OAB 
 
OAB presents a distinct entity of unpredictable and troublesome symptoms. Many 
individuals find the condition and its associated symptoms personally and socially 
devastating. It is not only episodes of incontinence that affect well-being - frequency 
and urgency also have considerable detrimental effects on daily activities. Patients 
with OAB use a variety of behavioural modification and coping skills to reduce the 
impact of their symptoms. These include toilet-seeking, restriction of fluid intake, 
dietary restrictions, limitation of physical activity, and in severe cases, limitation of 
social activities. A cycle of anxiety and distress regarding possible urine loss and 
embarrassment leads to a great psychological burden and various degrees of social 
isolation. 
 
OAB compromises patients' emotional well being. In the EPIC study, Irwin et al. (8) 














symptoms made them feel depressed, and 28% reported feeling very stressed. In the 
NOBLE study, Stewart et al (7) observed that OAB-patients had clinically and 
statistically higher depression scores, poorer sleep quality and lower levels of overall 
quality-of-life (QoL). 
 
OAB compromises patients' working lives. Irwin et al (27) found that more than 21% 
of the population was worried about interrupting meetings because of frequent trips to 
the toilet, and 3% of the population changed jobs or were fired because of their 
bladder control problems. UUI was also a factor in the patients’ employment 
decisions. OAB may as such impair a woman’s ability to function normally in the 
workplace and can result in job loss. 
 
Coyne et al. (28) matched 1434 OAB cases of the EPIC with designated controls. 
Participants with OAB reported significantly less work productivity and sexual 
satisfaction, higher rates of depressive symptoms and lower levels of overall health. 
 
OAB further results in significant costs to the patient and public healthcare. In the last 
year, two important studies demonstrated the considerable economic impact of OAB. 
The prevalence data derived from the EPIC study were combined with healthcare 
resource-use data to derive current direct and indirect annual cost of illness estimates 
for OAB in Canada, Germany, Italy, Spain, Sweden and the UK (29). The estimated 
total cost for patients with OAB in these countries is €9.7 billion. New data from the 
United States suggest that the economic burden of OAB is about five fold higher than 
older, non-comprehensive estimates (30). Total national costs of $65.9 billion are 
estimated.  
 
1.7    Pathophysiology of OAB 
 
In spite of recent advances, the pathophysiology of OAB remains poorly understood. 
Researchers have been left to use hypothetical reasoning to translate scientific 
observations to the clinical setting. What is becoming increasingly clear is that the 















Traditionally the etiology of “overactivity” has been understood as neurological or 
myogenic in basis. 
 
Neurogenic detrusor overactivity is caused either by the sensitization of the normally 
silent peripheral afferent nerves to the bladder, or by damage to the central inhibitory 
pathways that normally inhibit the voiding reflex (31). This can then trigger primitive 
voiding reflexes as seen in patients with multiple sclerosis, cerebrovascular events and 
Parkinson’s disease. There the end product is a disorder of the surrounding nerve 
supply. 
 
The myogenic basis of detrusor overactivity is thought to involve changes in the 
detrusor muscle itself, due to factors such as acidosis, hypoxia and structural changes, 
resulting in altered detrusor contraction (32). There the end product is abnormal 
properties of smooth muscle. 
 
New theories have recently been described. The role of the urothelium in regulating 
bladder function has led to the hypothesis of a mechanosensory basis for OAB. The 
urothelium seems to be involved in sensory mechanisms and can release chemical 
mediators (33). Localisation of afferent nerves next to the urothelium suggests that 
urothelial cells could be targets for neurotransmitters released from bladder nerves or 
that chemicals released by urothelial cells could alter afferent nerve excitability. There 
must be a balance between the two mechanisms. In pathological conditions, the 
balance becomes modified causing a shift that leads to overactivity. 
 
The autonomous bladder theory (34), which is also a relatively new hypothesis, 
suggests that the detrusor is modular. Each module is supplied by the myovesical 
plexus and there can be synchronisation of activity between modules. A network of 
interstitial cells is located beneath the urothelium. As gap junctions provide pathways 
for direct cell-to-cell communication, the interstitial cellular network may operate as a 
functional syncytium, integrating signals and responses in the bladder wall (35). 
‘Miscommunication’ can lead to overactivity. 
 
Oestrogen deficiency at the menopause is known to affect the collagen content of 














dermal thickness and elasticity of skin in postmenopausal women (36). Estrogens are 
also known to have an effect on the synthesis of collagen and the metabolism of 
collagen in the lower genital tract (37). Exogenous oestrogen affects the remodelling 
of collagen in urogenital tissues, changing the quality and quantity of collagen in 
postmenopausal women (38). Studies have indicated that exogenous oestrogen results 
in a reduction of total collagen concentration in the periurethral tissues, a decrease in 
the cross-linking of collagen and an increase in levels of collagen turnover markers in 
both continent and incontinent women (39). The increased bladder resting tension and 
contractility, combined with weaker supportive structure around the urethra, may alter 
the pressure balance in favour of leakage. Animal models have indicated that 
oestrogen significantly decreases the amount of collagen fibers, increases the amount 
of muscle fibers in the detrusor muscle and therefore decreases the collagen/smooth 
muscle ratio in the detrusor muscle and in the urethral muscle layer (40).  
 
Oestrogen given in pharmacological doses can have a significant hypertropic effect on 
bladder smooth muscle, resulting in increased contractile function. Other 
physiological effects of oestrogen include an increase in periurethral vascularity (41). 
The vascular network of the urethra plays an important role in the maintenance of 
urinary continence, accounting for one-third of urethral pressure (41). Estrogens 
influence central neurologic control of micturition, although their exact role is not 
fully understood. 
 
1.8    Conservative Management  
 
Current therapies for OAB are limited. The focus of much ongoing research is on the 
improvement of the management for bladder control problems.  
 
1.8.1     Bladder Training 
 
This forms the foundation of OAB treatment. A combination
 
of patient education, 
scheduled voiding and urge-suppression
 
techniques aim to restore bladder control. 
Patients are encouraged to gradually extend the time between voids and in doing so, 
to increase bladder capacity. Urge inhibition can be achieved by practicing 














which increases intra-abdominal pressure and exposes patients to visual cues that can 
trigger incontinence, patients are encouraged to pause, sit down if possible, relax, and 
contract pelvic floor muscles repeatedly to diminish urgency and prevent urine loss. 
When urgency subsides, they can proceed to the toilet at a normal pace.  The rationale 
for the use of bladder training is that it inhibits involuntary bladder contractions. The 
mode of action remains unclear. It is unknown whether it incorporates other aspects of 
the physiology and mechanisms of urinary continence or if it induces unspecified 
psychological pathways. In the process of patients being made aware of the situations 
that lead to incontinence, patterns of daily activity may change. These can include 
physical and/or psychological changes and are unique to each individual. It can take 
months to achieve but may help patients who are physically and mentally able to 
make these changes.   
 
In a review of this technique by Fantl (42), more than 50% of women in a community 
dwelling population with urinary incontinence showed a 50–75% reduction in 




randomised, controlled trials, largely involving middle-aged
 
women and 
women under 75 years of age who had urge or mixed
 
urge–stress incontinence, 
suggest that cognitively intact,
 
motivated patients respond positively to bladder 
training (43, 44). Data from a Cochrane review for 172 women from three trials 
comparing bladder training to no bladder training favoured bladder training, but 
confidence intervals were wide and no statistically significant differences were found 
for primary outcome variables (45). Clinical experience suggests that any effects of 
bladder training tend to wane over time. The length of follow up in most trials was too 
limited to assess this. 
 
From a practical point of view, behavioural therapy programs may be difficult to 
apply in many practices as they are time consuming. It does not help to tell patients to 
lengthen voiding intervals by simply ‘holding on’. Patients must be educated, trained 

















1.8.2     Pelvic Floor Exercise 
 
Patients are taught how to identify and exercise pelvic floor muscles. This can help in 
aborting detrusor contractions and can be as important as bladder training. It is 
thought that pelvic floor muscle exercises create a reflex inhibition of the bladder in 
addition to the provision of enhanced periurethral support. 
 
Nygaard et al (46) reported a significant decrease in the mean number of incontinent 
episodes per day in a sample of 71 women with detrusor instability after a 3-month 
course of pelvic floor muscle exercises. 44% percent of all enrolees had at least 50% 
improvement in the number of incontinent episodes per day. This increased to 56% of 
enrolees who completed the treatment course. Six months after completing the course 
of exercises approximately one third of all enrolees reported that they continued to 
note good or excellent improvement and desired no further treatment. 
 
In a Cochrane review two comparisons of bladder training with pelvic floor muscle 
training plus biofeedback included 164 women: none of the differences in the primary 
outcomes achieved statistical significance (45). 
 
1.8.3     Biofeedback  
 
This was first described more than 25 years ago (47). Patients are retrained within a 
closed feedback loop by making unconscious physiologic processes available as a 
visual or auditory stimulus. Improvement of at least 50% is common. It is time 
consuming and therefore seldom used as therapy today. 
 
1.8.4     Electrical stimulation  
 
This therapy has evolved over the past 40 years. Although the mechanism of action of 
electrical stimulation remains unproven in humans, most experts believe that non-
implanted electrical stimulation works by stimulating the pudendal nerve afferent 
nerves and that it affects striated muscle (48). It is also believed that neuromodulating 















In a review of the literature by Brubaker, good evidence for the use of electrical 
stimulators to reduce at least 50% of symptoms of OAB was presented (49). No 
economic analyses of this therapy are available, but its financial and technical 
limitations are well acknowledged.  
 
A neuromodulation device for posterior tibial nerve stimulation (PTNS) was released 
in the USA and UK for treatment of OAB.  It is based on the work done in the 1980s 
using an acupuncture needle placed in the posterior tibial nerve and passing an 
electric current through it (50).  This creates a feedback loop that neuromodulates 
bladder innervation. Although this treatment has no side effects and has success rates 
of between 60 – 80%, it requires multiple visits (weekly over 12 weeks) and a 
significant time commitment.  Several other investigators have since reported 
compelling results with the use of PTNS for the treatment of OAB, some of which 
have provided highly favourable comparisons to pharmacotherapy (51, 52). 
 
The Study of Urgent PC vs Sham Effectiveness in Treatment of Overactive Bladder 
Symptoms (SUmiT) was a multicenter, double-blind, randomized, controlled trial 
comparing the efficacy of percutaneous tibial nerve stimulation to sham therapy (53) . 
This is the first neuromodulation study to use a published validated sham component.  
 A total of 220 adults with overactive bladder symptoms were randomized to 12 
weeks of treatment with weekly percutaneous tibial nerve stimulation or sham 
therapy. Overactive bladder and quality of life questionnaires as well as 3-day voiding 
diaries were completed at baseline and at 13 weeks. Subject global response 
assessments were completed at week 13. The 13-week subject global response 
assessment for overall bladder symptoms demonstrated that percutaneous tibial nerve 
stimulation subjects achieved statistically significant improvement in bladder 
symptoms with 54.5% reporting moderately or markedly improved responses 
compared to 20.9% of sham subjects from baseline (p > 0.001). All individual global 
response assessment subset symptom components demonstrated statistically 
significant improvement from baseline to 13 weeks for percutaneous tibial nerve 
stimulation compared to sham. Voiding diary parameters after 12 weeks of therapy 
showed percutaneous tibial nerve stimulation subjects had statistically significant 














and urinary urge incontinence episodes compared to sham. No serious device related 
adverse events or malfunctions were reported. 
 
The trial provides level I evidence that percutaneous tibial nerve stimulation therapy 
is safe and effective in treating overactive bladder symptoms. 
 
The neuromodulator devices are expensive and their use is limited in the public health 
sector in South Africa. 
 
1.9    Medical Management 
 
Many classes of drugs, often used as an adjunct to various non-pharmacological 
therapies, have been studied for the treatment of OAB. The most commonly used 
medications to treat OAB have anticholinergic properties. Anticholinergics are 
competitive inhibitors of acetylcholine. These agents block the muscarinic effects and 
thereby inhibit involuntary bladder contractions. 
 
A Cochrane review favoured anticholinergic drugs compared with bladder training for 
symptomatic improvement of OAB (54). A combination of anticholinergics with 
bladder training was most effective.  
 
Several drugs, with different doses, formulations, and routes of administration are 
available in clinical use, but because of high costs, the use of these preparations in 
resource scarce environments is limited to immediate-release oral oxybutynin. 
 
Oxybutynin has anticholinergic effects and acts mainly on the muscarin-3 (M3) 
subtype receptors. These receptors are responsible for the contractile properties of the 
bladder. 
 
Given in the immediate-release oral formulation, oxybutynin has led to a clinically 
significant improvement, defined as a reduction in incontinence episodes by more 
than 50 percent, in approximately 60 to 80 percent of study subjects. (55.56). As such 
it is an effective drug, but patient compliance is poor because of its side effect profile 














receptor, and therefore dry mouth is a major side effect and the most common reason 
patients discontinue its use.  Dry mouth is reported in up to two thirds of subjects 
(57).  
 
Although dry mouth is most common, other bothersome side-effects including 
constipation, gastroesophageal reflux, blurry vision, urinary retention and cognitive 
impairment can occur. A starting dose of 2.5 mg daily is standard. This daily dose can 
be increased by 2.5 mg until there is a satisfactory response in symptoms or the 
adverse effects become too troublesome. The effective dose is found by titrating the 
medication to relieve the symptoms barring the limit of side effects on dosing. 
Reducing the dose might help to relieve the side effects and should be attempted 




































Acupuncture for OAB 
 
2.1     Available Evidence for acupuncture for OAB 
 
In a recent randomised, controlled trial, Emmons et al (58) compared treatment 
acupuncture with a placebo acupuncture for OAB.  A total of 74 women completed all 
aspects of the study and were analyzed. The treatment arm involved classic 
acupuncture in bladder specific points given weekly over four weeks, whereas the 
placebo arm included acupuncture in relaxation points. Although there was a 
reduction in the number of incontinence episodes in the treatment group compared to 
in the placebo group (59% vs. 40%), this difference was statistically insignificant.  
There were, however, statistically significant reductions in urinary frequency (14% 
vs. 4%, p<0.03) and urgency (30% vs. 3%, p<0.016) in the treatment group. In this 
group, maximum cystometric capacity increased by 12% compared to 4% in the 
control group, which was marginally statistically significant (p< 0.049). Most 
considerably, the quality of life, as assessed by the incontinence impact questionnaire 
score, showed an improvement in the treatment group (52% vs. 23%, p<0.004). 
Therefore, in this study, acupuncture had a significant short-term effect on OAB 
symptoms, similar in scope to the improvement offered by drug therapy and physical 
or behavioural therapy. 
 
In another interesting study, Kelleher et al (59) compared the efficacy of acupuncture 
to conventional anticholinergic drug therapy (oxybutynin) in the management of 
irritative bladder symptoms. The 39 patients in the study had not received any other 
treatment before study inclusion. Twenty patients received six weekly acupuncture 
treatments and 19 patients received daily oral oxybutynin. Both groups were reviewed 
weekly. Although urgency and frequency were significantly improved by both 
methods of treatment (60% and 67%; 26% and 18%; p<0.005), nocturia was 
significantly improved only by acupuncture (25%; p<0.05). There was no significant 
improvement in urge incontinence in either group. Unsurprisingly, the frequency of 
side effects was much higher in the group treated with anticholinergics. Both groups 














Three months following the last treatment, 8 of the 20 patients in the acupuncture 
group were symptom free versus 7 of the 19 patients in the oxybutynin group. This 
trial demonstrated that acupuncture was as effective as anticholinergic therapy in the 
management of irritative bladder symptoms, but without the adverse effects often 
associated with the drug therapy.   
 
Chang (60) allocated 52 women (age 17 to 52) with frequency and urgency to one of 
two groups. The first group received treatment acupuncture at the points used for 
urinary symptoms. The second group received acupuncture at the points used for 
gastrointestinal disease. All the participants underwent urodynamic measurements 
before and after acupuncture. Of the patients in the first group, 84% reported 
symptomatic improvement whereas only 23% of the patients receiving acupuncture at 
the gastro-intestinal points reported an improvement. It is not clear how this 
improvement was calculated and no statistical analysis was done. Presentation of 
these data makes it difficult to determine a specific result. The maximum cystometric 
capacity increased in 89% (p<0.01) and the peak urinary flow rate decreased in 77% 
of participants (p<0.02) after acupuncture at the bladder points. The investigators 
concluded that in the group receiving acupuncture at bladder points, detrusor activity 
was suppressed. Of note is that 54% of the patients had temporary improvement and 
required second and third treatments. 
 
There have been a number of non-controlled observational trials demonstrating the 
efficacy of acupuncture on bladder symptoms. Philip et al (61) successfully used 
acupuncture to treat patients with idiopathic detrusor overactivity. In their open non-
controlled study, 20 patients (aged 19 to 69) completed weekly acupuncture 
treatments for 10 to 12 weeks. 63% percent of their cohort became continent. The 
most marked finding was that in the group that showed the most dramatic 
improvement, frequency was completely abolished. In the subgroup with diurnal 
symptoms, there was significant symptomatic improvement in 10 out of 13 patients 
(77%). Urodynamic changes were, however, disappointing with few objective 
changes and no improvement in the pattern of the filling curves. They concluded that 
acupuncture is at least as effective as other non invasive treatments for diurnal 
symptoms of idiopathic detrusor overactivity, with the added advantage of no side 














designed and was open to bias during the follow-up assessment. A critical limitation 
of this study was that there was no statistical analysis done. 
 
Acupuncture also appears to improve enuresis in children. A report from Minni (62) 
described the effect of acupuncture in 22 children (age 5 to 12) with enuresis. All the 
children had acupuncture treatment once a week for 8-10 weeks. Clinically, a gradual 
elimination of enuresis was observed in 11 cases and an improvement in the other 
seven children. The authors concluded that acupuncture was effective in suppressing 
uninhibited bladder contractions in enuresis. It is well established that there is a 
significant spontaneous remission rate for childhood enuresis. This limits the findings 
of the study as results may not be applicable to adults. It is a small study and no 
statistical evidence for findings was given.  
 
In a small open clinical follow-up study by Bergstrom et al (63) significant 
improvement for 25 older women with urge- or mixed-type urine incontinence was 
documented after a series of twelve acupuncture treatments. Patients were followed-
up one and 3 months after treatment. Patients were found to only improve after the 8th 
treatment. The nocturia mean was significantly reduced at follow-ups (from 1.57 to 
0.97, p=0.004–0.009). The frequency mean did not show any significant changes. 
Urge and UI were both significantly reduced from baseline to three months after the 
treatment. QoL scores also improved significantly. At three months follow-up, there 
was a tendency for the improvement to decline, but this was not significant. The small 
sample size limits the validity of this study. 
 
The use of acupuncture for the treatment of detrusor overactivity in patients with 
chronic spinal cord injuries was investigated by Honjo et al. (64). A total of 13 
patients were treated. In this small study, incontinence disappeared in two and 
decreased by up to 50% in a further six patients.   
 
 
2.2 Possible Mechanism of Action 
 
Acupuncture has been used widely in the treatment of diseases in China for thousands 














traditional Chinese medicine, acupuncture is based on the theory that there are energy 
channels called meridians that run throughout the body and that disease results from 
blockages of this "life energy". Acupuncture is used as one method of releasing these 
blockages. Given the western, biomedical model, acupuncture is difficult to 
comprehend as there is no evidence to support the existence of these meridians. As 
acupuncture has become increasingly more accepted in the Western World, scientists 
have looked for westernised explanations to describe why it works and there is an 
intriguing and growing body of research on the topic. In the bladder, specifically, 
different physiological mechanisms might be at work. 
 
It is accepted that acupuncture partially works through the endorphinergic system (65, 
66). Endorphins are increased by acupuncture (67, 68). Enkephalins are endogenous 
ligands for endorphin receptors and have been demonstrated in lower urinary tract 
smooth muscle and in ganglia of the urinary bladder (69). Urinary bladder motility is 
depressed by enkephalins via activity on vesical ganglia (70). In animal studies it has 
been shown that the pontine micturition centre is under tonic inhibition from 
enkephalins (71) and that enkephalins injected intracerebroventricularly increase the 
threshold for micturition (72). Thus stimulation of the endorphinergic system seems to 
have an inhibitory effect on the pontine micturition centre and thus might help with 
bladder control.  
 
Acupuncture is a form of somatic sensory stimulation. In anaesthetised animals, Sato 
has shown that somatic afferent stimulation on the perineal area inhibits micturition 
contractions of the urinary bladder (73). 
 
Researchers at the University of Southampton and University College London have 
recently shown that the impact of acupuncture goes beyond the acknowledged 
placebo effect caused by the patient's own expectation of feeling benefit of treatment 
(74). Positron Emission Tomography scans were performed to explore the cerebral 
consequences in patients in three different arms of the study: real acupuncture, 
placebo acupuncture and skin prick only. They found that the insula ipsilateral to the 
site of needling was activated to a greater extent during real acupuncture than during 
the placebo intervention. Real acupuncture also caused greater activation than skin 














midbrain. These results suggest that real acupuncture has a specific physiological 
effect. 
 
2.3     Issues with design of acupuncture studies  
 
Many studies reporting different measures to improve irritative bladder symptoms are 
criticised for the significant placebo effect found in them. Little is understood about 
the complexities of the interaction between acupuncture, placebo, patient, and 
practitioner. This relative ignorance may be responsible for the confusing results of 
acupuncture trials and the lack of clarity emerging from systematic reviews. 
 
In placebo controlled trials of conventional treatment methods, approximately one 
third of patients experience a placebo response. Trials investigating the role of 
acupuncture in the treatment of OAB are no different. They present major 
methodological problems, particularly as we understand so little about the underlying 
biological mechanisms. 
 
The design of an appropriate placebo control group is also a major challenge. In trials 
of new drugs, double blinding is the accepted standard. However, since acupuncture is 
a procedure rather than a pill, it is difficult to design studies in which both the 
acupuncturist and patient are blinded as to the treatment being given. The same 
problem arises in double-blinding of virtually all surgical procedures. One proposed 
solution to blinding patients has been the development of ‘sham acupuncture’.  
Needling is performed superficially or at non-acupuncture sites. Controversy remains 
over whether sham acupuncture may function as a true placebo (75). 
 
‘Sham needling’ is not an inert equivalent for the treatment it mimics as it may be 
have a real effect similar to that of acupuncture. It is more than a placebo and does 
seem to have a therapeutic effect that negates its use as a real placebo. It could be seen 
as an active intervention in its own right - an intervention that is complex with 
multiple components and synergistic interaction (76).  
The debate for a true placebo for acupuncture is ongoing. Only with more rigorous 















2.4 Objectives of the study 
 
The objective of the study was to investigate acupuncture as a treatment modality to 
improve the symptoms of patients with refractive OAB.  
 
 The primary aim was to evaluate the effect on frequency, nocturia and UUI.  
 


































Patients and Methods 
 
3.1     Study design 
Twenty consecutive patients who regard their symptoms of OAB as not satisfactorily 
relieved by standard treatment were invited to participate and all agreed. The patients 
functioned as their own controls over a period of time. Each patient’s pre-treatment 
evaluation was compared to post-treatment evaluation at different points. All patients 
have received conventional treatments prior to recruitment. Fixed treatment regimes 
were not changed during the study. 
 
3.2 Study setting 
 
Recruitment took place at the Female Continence Clinic (FCC) at Groote Schuur 
Hospital (GSH) in Cape Town. GSH is one of the major teaching hospitals of the 
Associated Academic Hospitals' group and is an integral component of the Health 
Service of the Provincial Administration of the Western Cape, South Africa. The 
University of Cape Town is associated with Groote Schuur Hospital. The FCC is a 
tertiary level clinic which receives referrals from general practitioners, primary care 
clinics, district hospitals and secondary level hospitals in its catchment area. 
The patient population consists mainly of individuals of middle to low socio-
economic status. 
 
3.3     Subject selection 
The participants were women with OAB that is refractive to standard treatment given 
at our specialised unit. Standard treatment involves concurrent behavioural and 
pharmacology treatment. Potential participants were identified by consultants and 
registrars from the Department of Gynaecology and Department of Urology who staff 

















 Inclusion criteria 
1. Aged ≥18 years. 
2. Refractive OAB. 
3. Able to give informed consent. 
 
Exclusion criteria 
Patients known with conditions that can cause similar symptoms as OAB was 
excluded. Treatment naïve patients and patients with mainly stress incontinence were 
also excluded. 
1. Mixed Incontinence with Stress Incontinence as dominant symptom. 
2. Urinary tract infection. 
3. Urinary tract obstruction. 
4. Interstitial cystitis. 
5. Urinary Tract Fistula. 
6. Urethral diverticulum. 
7. Urogenital tumours. 
8. Cerebrovascular lesions, dementia, Parkinson’s disease and multiple sclerosis. 
9. Pregnancy or recent birth.  
10. Acupuncture
 
treatments for any other condition. 
11. Needle phobia. 
12. Newly diagnosed patients with OAB that have not completed at least three 
months of pharmacological treatment. 
13. Newly diagnosed patients with OAB that have not completed at least three 
months of behavioural therapy. 
 
3.4     Acupuncture Treatment 
 
Acupuncture was performed weekly for four weeks (see time line below). Disposable 
stainless steel needles that were 0.22 mm wide and are
 
50-mm long were used for the 
procedures. The acupuncture was performed by experienced physiotherapists and 
supervised by a consultant urogynaecologist who is board-certified in medical 
















 Bilateral Sanyinjiao, Sp6; 4 cunˡ  superior to the tip of the medial malleollus. 
 
 Bilateral Weiyang, BL 39; at the lateral end of the popliteal crease, medial to 
the tendon of biceps femoris. 
 
 Bilateral Pangguangshu, BL 28; in the depression, 1.5 cunˡ  lateral to the 
midline between the lower medial border of the posterior superior iliac spine 
and the sacrum. 
 
 Midline Guan Yuan, CV4; on the saggital line, two cunˡ  superior to the crest 
of the pubic symphysis. 
 
ˡ  The cun is a measurement relative to the patient’s body that is used to find 
acupuncture points. One cun is equal to the space between the distal interphalangeal 
joint and the proximal interphalangeal joint on the middle finger. 
 
Traditionally these points have been used in the treatment of urinary problems.  
 
An acupuncture point-finder was used to aid in identifying the acupuncture points. It 
comprises of a point finder electrode that is passed over a patient's skin, an electrode 
held by the patient and a balancing and sensitivity adjustment circuit electrically 
connected to the point finder and electrodes so as to produce an imbalance signal 
when the point finder electrode passes over an acupuncture point. An amplifier circuit 
is provided in connection with the balancing and sensitivity adjustment circuits that 
generate an audio signal. The point finder was only used during the first treatment. 
Thereafter the points were marked with long lasting dye.  
 
Needles were inserted at the same 7 points during each of the weekly sessions and 


















3.5     Study Time Line 
 




A:  ‘week 6’ refers to 5 completed weeks after the first acupuncture 
B:  week 13 refers to 12 completed weeks after the first acupuncture and will be referred to as ‘3 months’ in the study 
 
 
3.6     Data Collection 
 
3.6.1     Recruitment 
Demographic data was gathered by completing the data collection sheet (Refer to 
appendix 1). Following this, each participant completed the King’s Health 















3.6.2     Measurements 
 
The bladder diary 
Participants kept three-day bladder diaries (Refer to appendix 3) at three different 
times during the study:  prior to treatment, at week 6  and at 3 months (Refer to time 
line). These data collecting points are similar than that of the Emmons trial (58). 
Participants recorded the frequency of day and night time voiding and incontinence 
episodes over three day periods. Bladder diaries are commonly used for assessment of 
treatment outcome in both clinical practice and research studies (62, 63).  
 
The King’s Health Questionnaire 
Each participant’s QoL was assessed at three different times during the study:  prior to 
treatment, week 6 and 3 months (Refer to time line). The King’s Health Questionnaire 
was used for this purpose. This is a condition-specific health-related quality-of-life 
instrument for the assessment of patients with lower urinary tract conditions including 
OAB. The questionnaire was designed at a tertiary referral urogynaecology unit at 
King's College Hospital, London, following six different pilot studies (64). The 
questionnaire was shown to be reliable both by test-retest analysis and by 
measurement of its internal consistency.  The questionnaire was found to be a valid 
and reliable instrument for the assessment of QoL in women with urinary 
incontinence (65).  
 
The questionnaire translates into two general domains - General Health and 
Incontinence Impact - and seven lifestyle domains comprising of Role Limitation, 
Physical Limitation, Social Limitation, Personal Limitation, Emotional Limitation, 
Sleep Limitation and Severity Scoring.  Scores range from 0 to 100; where 100 is the 
worst possible condition and 0 means that there is no influence on daily living. A 
decrease in the score therefore means improvement in QoL. 
 
3.7     Statistical Analysis 
 
Demographic data was entered into Microsoft Excel and analysed using SPSS 















Data from the bladder dairies and the KHQ was collected at successive time intervals 
and analysed. Fisher's Least Significant Difference (LSD) procedure was used. The 
null hypothesis was tested with Analysis of Variance (ANOVA). Pairwise 
comparisons of the self-control groups were done.  
 
Statistical significance was defined at p≤ 0.05.  
 
3.8     Ethics  
 
Written consent was obtained in the patients’ language of choice (Refer to appendix 4, 
appendix 5 and appendix 6). The consent form also contained information regarding 
the aim of the study, acupuncture treatment and time line. 
 
Ethical approval was obtained from the Research Ethics Committee of the Faculty of 
Health Sciences of The University of Cape Town (REC REF: 009/2009). 
 
All aspects of the study complied with the Declaration of Helsinki, Sixth revision, 
































4.1     Patient Characteristics  
 
A total of 20 women were recruited into the study. All invited patients agreed to 
participate. One participant did not complete the trial due to work commitments. 
 
Table 1 shows the patient characteristics of the study group. The mean age of the 20 
study participants was 51 years (Standard Deviation, 10.1) with only three patients 
included who were less than 40 years of age. The mean body mass index was 31 
(Standard Deviation, 7.2). 
 
Most women recruited into the study were of mixed race (80%). Most study 
participants (90%) had at least one year of secondary education. Of the participants 
55% were in a stable relationship and 60% were sexually active. Eighty-five percent 
of the women recruited into the study had at least one vaginal delivery. The minority 
had instrumental deliveries and episiotomies.  
 
Most of the women were postmenopausal (75%) and 25% had a history of previous or 
current hormone therapy use. Only 5% of participants were still on HRT. Thirty 
percent of the patients had a previous hysterectomy and only 5% had prolapse 
symptoms at presentation. 40% of patients had a previous anterior vaginal repair 
procedure. The minority of patients had stress-incontinence surgery and surgery for 
posterior compartment prolapse. 
 
More than half of the study group were treated for hypertension (65%); half of these 



















Table 1: Patient Characteristics  
Age, mean (standard deviation)   51 (10.064) 
Body mass index, mean (standard deviation) 31 (7.240) 
Race:   
     Mixed Race 18 (90) 
     White 2 (10) 
Education:   
     At least secondary level 18 (90) 
Interpersonal relationship   
     In stable relationship 11 (55) 
Habits:   
     Smoking 8 (40) 
Obstetric history:   
     Vaginal delivery 
1
 17 (85) 
     Instrumental delivery
2
  4  
     Episiotomy 5 (25) 
Gynaecological history:   
    Postmenopausal 15 (75) 
    Previous hormone therapy use 5 (25) 
    Hysterectomy
3
 6 (30) 
    Prolapse symptoms 5 (25) 
Medical history:   
     Hypertension 13 (65) 
     Current diuretic use 7 (35) 
     Diabetes  5 (25) 
Gynaecological surgical history:   
     Anterior vaginal repair 8 (40) 
     Posterior vaginal repair 2 (10) 
     Stress incontinence surgery 
4
 5 (25) 
 Special Investigations:    
     Cystoscopy 10 (50) 















1 one never pregnant, one only miscarriages, one only c-sections 
2 three forceps deliveries, one vacuum extraction 
3 two abdominal, four vaginal  
4 details unknown 
 
On 75% of participants urodynamic studies were performed. It is not clear why this 
was not done in the other 25% of participants.  
 
Only 50% of patients had a cystoscopy. Therapies directed toward the uroepithelial 
dysfunction and neural up regulation associated with interstitial cystitis/painful 
bladder syndrome may be an important adjunct for patients who have failed or have 
had a partial response to anticholinergic therapy and behaviour modification. 
Cystoscopy should therefore be indicated in patients with a history of refractive 
symptoms and recurrent urinary tract infection. Although some urogynaecology units 
suggest that all patients in whom symptoms of overactive bladder develop should 
undergo cystoscopy to rule out carcinoma in situ and other intravesical abnormalities, 
the cost effectiveness of this approach is uncertain.  
 
 
Table 2 shows symptoms of OAB at initial presentation to FCC and at the time of 
study enrolment. Symptoms included urinary frequency, urinary urgency, urge 
incontinence and nocturia. The median time interval between onset of symptoms and 
study enrolment was six years (Inter Quartile range, 4-13 years). The frequency of 
symptoms were similar between initial presentation to FCC and study recruitment; 
urinary frequency, nocturia and urinary urgency were all present in the majority of 
patients at initial presentation (95%, 80% and 100%, respectively) and at study 





















Table 2: Overactive bladder symptoms at presentation and recruitment 
 
 Symptom Initial Current 
Frequency 19 (95) 20 (100) 
Nocturia 16 (80) 18 (90) 
Urgency 20 (100) 20 (100) 
Urge Incontinence 11 (55) 8 (40) 
 
 
Table 3 reflects the conservative management strategies of patients at our unit prior to 
enrolment. At time of enrolment, 65% of patients were still practising pelvic floor 
exercises and 35% of patients were still receiving oxybutynin. The dose of 
oxybutynin varied according to therapeutic response and side effects. The majority of 
patients discontinued oxybutynin due to ineffectiveness and intolerance. In addition to 
standard treatments, four patients (20%) also received bladder installations. Notably, 
at recruitment, none of the participants were utilizing bladder training to control 
symptoms. 
 
Table 3: Management strategies of patients with overactive bladder syndrome prior to 
enrolment. 
 Median duration, years 





Pelvic floor exercises 1 (1-4) 13 (65%) 
Bladder training 0.5 (0.3- 0.6) 0  
Oxybutynin 3.5 (1.75-6) 7 (35%) 
 





















4.2     Bladder Diaries 
 
4.2.1     Frequency 
 
Table 4 represents the mean frequency over three days for the three different intervals. 
At recruitment it was 32. This decreased to 26 and 25 at week 6 and 3 months 
respectively. 
 
Table 4:  Frequency means 
 
 Mean Lower  95% CI Upper 95%  CI 
FREQ1ˡ  32 21 44 
FREQ2
2
 26 18 33 
FREQ3
3
 25 17 34 
 
1 frequency at baseline 
2 frequency at week 6 






























Figure 2:  Analysis of Variance for frequency means 
 
FREQ; LS Means
Current effect: F(2, 38)=7.8398, p=.00141
Effective hypothesis decomposition

















There is a difference between the groups (p=0.001). 
 
Table 5: Comparisons of frequency means using Fisher’s Least Significant Difference  
 
 FREQ {1} {2} {3} 
1 FREQ1  0.001680 0.001293 
2 FREQ2 0.001680  0.926166 
3 FREQ3 0.001293 0.926166  
 
There was a significant decrease in frequency from baseline to week 6 (p=0.002) and 
















4.2.2     Nocturia 
 
Table 6 represents the mean number of nocturia over three days for the three different 
intervals. At recruitment it was 10. This decreased to 6 at week 6 and increased to 7 at 
3 months. 
 
Table 6: Nocturia means 
 
 Mean Lower  95% CI Upper 95%  CI 
NOCT1ˡ  10 5 15 
NOCT2
2
 6 4 8 
NOCT3
3
 7 4 9 
 
1 nocturia at baseline 
2 nocturia at week 6 
































Figure 3: Analysis of Variance for nocturia means 
NOCT; LS Means
Current effect: F(2, 38)=5.3763, p=.00879
Effective hypothesis decomposition















 There is a difference between the groups (p=0.009). 
 
Table 7: Comparisons of nocturia means using Fisher’s Least Significant Difference 
 
 NOCT {1} {2} {3} 
1 NOCT1  0.004044 0.014920 
2 NOCT2 0.004044  0.612973 
3 NOCT3 0.014920 0.612973  
 
There was a significant decrease in nocturia from baseline to week 6 (p=0.004) and 



















4.2.3     Incontinence 
 
Table 8 represents the mean number of incontinence over three days for the three 
different intervals. At recruitment this was 9. This decreased to 7 and 6 at week 6 and 
3 months respectively. 
 
Table 8: Incontinence means 
 
 Mean Lower  95% CI Upper 95%  CI 
LEAK1ˡ  9 4 14 
LEAK2
2
 7 3 12 
LEAK3
3
 6 1 11 
 
1 incontinence at baseline 
2 incontinence at week 6 































Figure 4: Analysis of Variance for incontinence means 
LEAK; LS Means
Current effect: F(2, 38)=8.0460, p=.00122
Effective hypothesis decomposition

















 There is a difference between the groups (p=0.001). 
 
Table 9: Comparisons of incontinence means using Fisher’s Least Significant 
Difference 
 LEAK {1} {2} {3} 
1 LEAK1  0.016658 0.000312 
2 LEAK2 0.016658  0.152195 
3 LEAK3 0.000312 0.152195  
 
There is a significant decrease in incontinence from baseline to week 6 (p=0.02) and 
from baseline to 3 months (p=0.0003). There is no further significant decrease from 


















4.3 The King’s Health Questionnaire  
 
4.3.1     KHQ: General Health 
Table 10 represents the mean score in General Health as documented on the KHQ at 
baseline and week 6 and 3 months respectively. This score is calculated out of 100 
where 0 represents no influence on QoL. 
 
Table 10: General Health score means 
 Mean Lower  95% CI Upper 95%  CI 
genh1ˡ  57 46 67 
genh2
2
 49 39 58 
genh3
3
 43 37 50 
1 general health score at baseline 
2 general health score at week 6 
































Figure 5: Analysis of Variance for General Health score means 
GENH; LS Means
Current effect: F(2, 36)=5.5385, p=.00800
Effective hypothesis decomposition


















There is a difference between the groups (p=0.008). 
 
Table 11: Comparisons of General Health score means using Fisher’s Least 
Significant Difference 
 
 GENH {1} {2} {3} 
1 genh1  0.054951 0.002150 
2 genh2 0.054951  0.194345 
3 genh3 0.002150 0.194345  
 
There was a marginal improvement in general health scores from baseline to week 6 
(p=0.05), but a significant improvement from baseline to 3 months (0.002).There was 















4.3.2     KHQ: Incontinence Impact 
 
Table 12 represents the mean score in Incontinence Impact as documented on the 
KHQ at baseline and week 6 and 3 months respectively.  
 
Table 12: Incontinence Impact scores means 
 
 Mean Lower  95% CI Upper 95%  CI 
incontim1ˡ  68 57 79 
incontim2
2
 59 48 71 
incontim3
3
 56 44 68 
 
1 incontinence impact score at baseline 
2 incontinence impact score at week 6 

































Figure 6: Analysis of Variance for Incontinence Impact score means 
INCONT; LS Means
Current effect: F(2, 36)=4.0569, p=.02577
Effective hypothesis decomposition


















There is a difference between the groups (p=0.026). 
 
Table 13: Comparisons of Incontinence Impact score means using Fisher’s Least 
Significant Difference 
 
 INCONT {1} {2} {3} 
1 incontim1  0.055326 0.008960 
2 incontim2 0.055326  0.438910 
3 incontim3 0.008960 0.438910  
 
There is no difference between incontinence impact at baseline and at week 6 
(p=0.055). There is a significant improvement in impact scores from baseline to 3 
















4.3.3     KHQ: Role limitation 
 
Table 14 represents the mean score in Role Limitation as documented on the KHQ at 
baseline and week 6 and 3 months respectively.  
 
Table 14: Role Limitation score means 
 
 Mean Lower  95% CI Upper 95%  CI 
rolelim1ˡ  54 42 67 
rolelim2
2
 42 30 54 
rolelim3
3
 36 25 47 
1 role limitation score at baseline 
2 role limitation score at week 6 

































Figure 7: Analysis of Variance for Role Limitation score means 
 
ROLELIM; LS Means
Current effect: F(2, 36)=10.847, p=.00021
Effective hypothesis decomposition




















There is a difference between the groups (p=0.0002). 
Table 15: Comparisons of Role Limitation score means using Fisher’s Least 
Significant Difference 
 
 ROLELIM {1} {2} {3} 
1 rolelim1  0.004294 0.000055 
2 rolelim2 0.004294  0.135864 
3 rolelim3 0.000055 0.135864  
 
There was a significant improvement in role limitation scores from baseline to week 6 
(p=0.004) and from baseline to 3 months (0.00005). There was no difference between 

















4.3.4     KHQ: Physical Limitation 
 
Table 16 represents the mean score in Physical Limitation as documented on the KHQ 
at baseline and week 6 and 3 months respectively.  
 
Table 16:  Physical Limitation score means 
 
 Mean Lower  95% CI Upper 95%  CI 
physlim1ˡ  46 30 63 
physlim2
2
 36 23 49 
physlim3
3
 34 20 48 
1 physical limitation score at baseline 
2 physical limitation score at week 6 
































Figure 8: Analysis of Variance for Physical Limitation score means 
 
PHYSLIM; LS Means
Current effect: F(2, 36)=6.8029, p=.00312
Effective hypothesis decomposition




















 There is a difference between the groups (p=0.003). 
 
 
Table 17: Comparisons of Physical Limitation score means using Fisher’s Least 
Significant Difference 
 PHYSLIM {1} {2} {3} 
1 physlim1  0.005984 0.001612 
2 physlim2 0.005984  0.627405 
3 physlim3 0.001612 0.627405  
 
There was a significant improvement in physical limitation scores from baseline to 
week 6 (p=0.006) and from baseline to 3 months (0.002). There was no difference 
















4.3.5     KHQ: Social Limitation 
 
Table 18 represents the mean score in Social Limitation as documented on the KHQ 
at baseline and week 6 and 3 months respectively.  
 
Table 18: Social Limitation score means 
 
 Mean Lower  95% CI Upper 95%  CI 
soclim1ˡ  36 24 49 
soclim2
2
 26 17 35 
soclim3
3
 28 17 39 
1 social limitation score at baseline 
2 social limitation score at week 6 































Figure 9: Analysis of Variance for Social Limitation score means 
SOCLIM; LS Means
Current effect: F(2, 36)=9.0785, p=.00064
Effective hypothesis decomposition


















 There is a difference between the groups (p=0.0006). 
Table 19: Comparisons of Social Limitation score means using Fisher’s Least 
Significant Difference 
 
 SOCLIM {1} {2} {3} 
1 soclim1  0.000316 0.002184 
2 soclim2 0.000316  0.498452 
3 soclim3 0.002184 0.498452  
 
There was a significant improvement in social limitation scores from baseline to week 
6 (p=0.0003) and from baseline to 3 months (0.002). There was not a statistically 
















4.3.6     KHQ: Personal Limitation 
 
Table 20 represents the mean score in Personal Limitation as documented on the 
KHQ at baseline and week 6 and 3 months respectively.  
 
Table 20: Personal Limitation score means 
 
 Mean Lower  95% CI Upper 95%  CI 
perslim1ˡ  32 13 50 
perslim2
2
 26 8 44 
perslim3
3
 27 9 45 
 
1 personal limitation score at baseline 
2 personal limitation score at week 6 

































Figure 10: Analysis of Variance for Personal Limitation score means 
PERSLIM; LS Means
Current effect: F(2, 36)=3.5128, p=.04040
Effective hypothesis decomposition



















 There is a difference between the groups (p=0.04). 
 
Table 21: Comparisons of Personal Limitation score means using Fisher’s Least 
Significant Difference 
 
 PERSLIM {1} {2} {3} 
1 perslim1  0.020845 0.038278 
2 perslim2 0.020845  0.791657 
3 perslim3 0.038278 0.791657  
 
There was a significant improvement in personal limitation scores from baseline to 
week 6 (p=0.02) and from baseline to 3 months (0.04). There was no difference 

















4.3.7     KHQ: Emotional Limitation 
 
Table 22 represents the mean score in Emotional Limitation as documented on the 
KHQ at baseline and week 6 and 3 months respectively.  
 
Table 22: Emotional Limitation score means 
 Mean Lower  95% CI Upper 95%  CI 
emolim1ˡ  50 38 62 
emolim2
2
 31 22 40 
emolim3
3
 26 18 34 
 
1 emotional limitation score at baseline 
2 emotional limitation score at week 6 

































Figure 11: Analysis of Variance for Emotional Limitation score means 
 
EMOLIM; LS Means
Current effect: F(2, 36)=19.551, p=.00000
Effective hypothesis decomposition





















 There is a difference between the groups (p=0.00000). 
 
 
Table 23: Comparisons of Emotional Limitation score means using Fisher’s Least 
Significant Difference 
 
 EMOLIM {1} {2} {3} 
1 emolim1  0.000038 0.000001 
2 emolim2 0.000038  0.227850 















There was a significant improvement in emotional limitation scores from baseline to 
week 6 (p=0.00004) and from baseline to 3 months (0.000001). There was no 
difference between week 6 and 3 months (p=0.2). 
 
4.3.8     KHQ: Sleep Limitation 
 
Table 24 represents the mean score in Sleep Limitation as documented on the KHQ at 
baseline and week 6 and 3 months respectively.  
 
Table 24: Sleep Limitation score means 
 Mean Lower  95% CI Upper 95%  CI 
sleeplim1ˡ  47 38 57 
sleeplim2
2
 38 30 45 
sleeplim3
3
 39 30 48 
 
1 sleep limitation score at baseline 
2 sleep limitation score at week 6 






























Figure 12: Analysis of Variance for Sleep Limitation score means 
SLEEPLIM; LS Means
Current effect: F(2, 36)=4.9897, p=.01223
Effective hypothesis decomposition
















 There is a difference between the groups (p=0.012). 
 
 
Table 25: Comparisons of Sleep Limitation score means using Fisher’s Least 
Significant Difference 
 
 SLEEPLIM {1} {2} {3} 
1 sleeplim1  0.005347 0.020356 
2 sleeplim2 0.005347  0.594078 
3 sleeplim3 0.020356 0.594078  
 
There was a significant improvement in sleep limitation scores from baseline to week 
6 (p=0.005) and from baseline to 3 months (0.02). There was no difference between 















4.3.9     KHQ: Severity Scoring 
 
Table 26 represents the mean Severity Scoring as documented on the KHQ at baseline 
and week 6 and 3 months respectively.  
 
Table 26: Severity Scoring means 
 Mean Lower  95% CI Upper 95%  CI 
sevscore1ˡ  58 46 69 
sevscore2
2
 46 34 58 
sevscore3
3
 42 32 53 
 
1 severity scoring at baseline 
2 severity scoring at week 6 

































Figure 13: Analysis of Variance for Severity Scoring means 
 
SEVSCORE; LS Means
Current effect: F(2, 36)=13.207, p=.00005
Effective hypothesis decomposition



















There is a difference between the groups (p=0.00005). 
 
Table 27: Comparisons of Severity Score means using Fisher’s Least Significant 
Difference 
 SEVSCORE sevscore1 sevscore2 sevscore3 
1 Sevscore1  0.000718 0.000018 
2 Sevscore2 0.000718  0.222696 
3 Sevscore3 0.000018 0.222696  
 
There was a significant improvement in severity scores from baseline to week 6 
(p=0.0007) and from baseline to 3 months (0.00002). There was no difference 



















In this study of women with refractive OAB, acupuncture produced significant 
symptomatic and quality-of-life improvement in all outcomes measured.    
 
5.1     Key findings from the Bladder Diaries 
 
Bladder diaries were used in our study to evaluate the effectiveness of acupuncture in 
reduction of frequency, nocturia and urine incontinence caused by refractive OAB. 
We observed a reduction in all symptoms. 
 
 There was a 22% (p=0.002) and 23% (p=0.002) decrease in frequency from 
baseline to week 6 and to 3 months respectively. 
 There was a 38% (p=0.004) and a 31% (p=0.015) decrease in nocturia from 
baseline to week 6 and to 3 months respectively. 
 There was a 20% (p=0.002) and a 32% (p=0.0003) decrease in incontinence 
from baseline to week 6 and to 3 months respectively.  
 
The clinical significance of improvement in bladder control and symptoms of OAB is 
still undecided in urogynaecological circles. For that reason the QoL of patients must 
be evaluated to gage the level of clinical significance. 
 
5.2     Key findings from the Kings’ Health Questionnaire 
 
Questionnaires were used in our study to evaluate the effectiveness of acupuncture in 
improving the self-perceived QoL of the participants. We observed an improvement. 
 
 Both the general domains, General Health and Incontinence Impact, showed 














 All seven lifestyle domains showed significant improvement at week 6 and 
again at 3 months. Most significantly was a decrease in Emotional Limitations 
(p=0.00004 at week 6 and p=0.000001 at 3 months).  
 
The significance in overall improvement of QoL indicate that the improvement seen 
in bladder control could  also be clinically significant. 
  
5.3     Discussion of the Participant Characteristics 
 
The complexity of this cohort is clearly displayed in their characteristics. 
 
The mean age of the 20 study participants was 51 years (Standard Deviation, 10.1). In 
a 2010-comparison by Helfand et al (82) of over seven million people with the 
diagnosis of OAB, as recorded by 85 health care plans in America, the overall 
prevalence of OAB increased as a function of age: 4.9% of all patients were 45–54 
years of age, 6.7% of patients were 55–64 years of age, and 9.6% of patients were >65 
years of age. OAB seems to become a more significant clinical problem with age, but 
most of our participants were in the younger category. We suspect that many elderly 
patients in our population believe that urine incontinence is a normal part of aging and 
might not discuss this symptom with their health care workers. 
 
The mean body mass index was 31 (Standard Deviation, 7.2). It has long been 
recognized that obesity is a risk factor for all types of UI and this trend was also seen 
in our participants. 
 
In our study, 85% of the women had at least one vaginal delivery. Evidence suggests 
that the risk of OAB is not increased by vaginal births (15, 25). Interestingly, in a 
prospective study of 344 women, van Brummen et al (83) found that bothersome UUI 
was more prevalent after a Caesarean Section than a vaginal delivery.  
 
The black population seems to be unrepresented at the FCC and this is reflected in our 
study as none was recruited. As discussed in the introduction, we suspect that this 















A recent investigation by Coyne et al (84) found a similar impact of OAB on sexual 
health as in our study. Although few of the participants in our study (10%) reported 
incontinence during sexual intercourse on completion of the KHQ (see appendix 2), 
the majority expressed a fear of this and blamed OAB for decreased sexual desire. 
 
Treatment of OAB seems to fail in achieving the anticipated response in some 
patients treated at our unit. It is difficult to explain. This is probably due to a 
combination of factors. It is possible that some patients are not as motivated as others 
in persisting with behavioural techniques. It is also possible that some patients are 
more sensitive to side effects of the anticholinergic medication used,  Most of the 
patients in our study seemed eager to improve their bladder control, but 35% stopped 
performing pelvic floor exercises and none were practising bladder training. This is 
still considered to be the cornerstone of treatment for OAB. Many studies have 
documented this decline in the active involvement of OAB management from patients 
suffering from it (42-45).  
 
5.4     Comparison with other studies 
 
In a recent randomised-controlled trial, Emmons et al (58) compared treatment 
acupuncture with a placebo acupuncture for OAB.  The treatment arm involved the 
same bladder specific acupuncture points at the same intervals compared to in our 
study. Participant in their study had only one follow-up at 2-4 weeks after the 
treatment. We compared our results at week 6 (two weeks after treatment) with their 
results.  Frequency decreased more in our study compare to theirs, 22% versus 14%, 
but incontinence improved much more in their study, 59% versus 20%. We suspect 
this reflects the notable difference in the populations.  In our study, participants 
represented a complex group of patients that were refractive to treatment. In their 
study, participants were treatment naive. Similarly they found a significant 
improvement in QoL (p=0.004), but different questionnaires were used so domains 
cannot be compared directly. 
 
Kelleher et al (59) compared the efficacy of acupuncture to oxybutynin in the 
management of OAB. Different acupuncture points were used and participants in the 














results seem to be similar to ours. In comparison, frequency improved with 22% in 
our study versus 26% in theirs, nocturia improved with 31% versus 25%. Interestingly 
there was no improvement in UI in their study. 
 
The methodology of other acupuncture studies for irritative bladder symptoms (60-64) 
differ to such an extent that we cannot compare the data. 
 
5.5 Practical Points 
 
Acupuncture is time consuming for the patient and for the health care provider. 
Patients would have to be motivated to return for repeated treatments and a dedicated 
team of urogynaecologists and physiotherapist would be needed to feasibly employ it 
in a busy clinic.  Advantages of acupuncture are that the needles are cheap and the 
intervention safe (85) and does not impact on nursing staff duties. 
 
5.6 Strength of the study 
 
To the best of our knowledge this is the first report of the use of acupuncture as a 
treatment for OAB in a cohort that is refractive to treatment given at a specialised unit 
in a resource limited setting. 
 
5.7     Limitation of the study 
 
We acknowledge the possibility that the patient's own expectation of benefiting from 
the treatment may contribute to a significant placebo effect in our study. One can 
argue that in our study, the type of patient recruited may be less susceptible to placebo 
effect as they did not respond to previous therapy. Nevertheless, there remains a 
certain limitation.  
 
We acknowledge that our study is also limited by the availability of a good placebo
 
for acupuncture (refer to discussion 2.3 of issues with study design of acupuncture 
studies).  
 















In other larger scale studies QoL questionnaires were completed by the patients 
without assistance. In our study participants needed guidance and therefore all 
questionnaires were completed with the assistance of a medical doctor. Criticism 
against this way of data collection might be that it intrudes social bias. As the 
assistance was given to all of the participants by the same experienced doctor, we 
hope to have limited this.  
 
In our study ICS definitions were used (3). OAB as a symptom complex is defined 
from the individual's perspective and not based on urodynamic studies. Still we 
acknowledge that urodynamic studies could have added to the findings of our study. 
 
5.8     Implications for future research 
 
Western perception of complementary medicine must not constrain the performance 
of clinical research in this field. In our study, acupuncture had a significant short-term 
effect on OAB. These results need to be confirmed with a larger sample randomised-
controlled trial comparing acupuncture to a relevant placebo. Trials should be 
extended to see whether the effect is sustained beyond three months. To date there has 
not been a well constructed longitudinal long-term follow up study of patients that 
received acupuncture for OAB. 
 
Responders should be evaluated against non responders in an attempt to characterise 
these groups. 
 
Very little data is available for patients with OAB in South Africa.  As discussed in 
the introduction, there are no South-African prevalence studies presumably because of 
challenges arising from misconceptions of the condition in the general population. 
These studies must be undertaken. 
 
There is a need for a validated, standardised South African questionnaire for urinary 
incontinence to ensure consistency in future research in our country. These 














improvement and ‘subjective’ benefit is a complex issue and should be addressed in 
ongoing research. 
 
The use of an internationally accepted definition must be emphasised. An interesting 
project would be to evaluate South African gynaecologists’ concept of OAB and the 
definitions that they use. 
 
More studies are required to fully understand the association between diuretic use and 
OAB, particularly its impact on health-related QoL. 
 
Patients seem to be erratic in their practice of bladder training. There are no trials to 
address the value of later reinforcement of this technique. This strategy might have an 
important impact on refractive OAB.  
 
5.9     Implications for practice 
 
In our study, acupuncture for women with refractive OAB was effective in reducing 
symptoms and improved QoL.  Care must be taken in extending these findings to all 
patients with OAB. The study assessed women with refractive OAB to standard 
treatment in a resource limited setting.  Before implementing the treatment into 


























OAB is under the spotlight. We now recognize the tremendous number of patients 
with this problem. The burden on the individual patient and the potential economic 
impact is staggering. 
Health care in South Africa is economically under resourced. Treatment modalities 
for OAB are limited to bladder training and oral immediate release oxybutynin. Some 
patients fail to respond. There is currently no alternative therapy available to them. 
In this study of women with refractive OAB, acupuncture produced significant 
symptomatic and QoL improvement in all outcomes measured.    
 
Acupuncture as a low risk intervention is safe and well tolerated by patients. Even 
without substantial grade I evidence, there is support for the possible benefit of 
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Appendix 1:  Data collection 
 
Study number _________________ 
Age   _________________ 
Weight_________________Height_________________BMI_________________ 
1. Demographics 
1 A Race :   
 Coloured= 1, White= 2, Black= 3, Indian= 4, other=5 
 
1 B Marital status: 
 Married=1, single=2, divorced=3, Living with partner=4, widow=5 
 
1 C Education: 




2 A Smoking: 
2 A 1 Yes=1, No=2   
2 A 2 If yes: Pack year history 
2 B Alcohol: 
Yes=1, No=2,  
if yes: unit/ weeks 
 
 
3 Obstetric History 
3 A Gravity  
3 B Parity  
















3 G Number of C/sections  
 
4 Gynaecological History 
4 A Post menopausal :  Yes=1, No=2  
4 B If yes: Age of menopause 
4 C HRT use 
Previous=1, current=2, never=3 
 
4 D If previous of current: Type of HRT 
Oestrogen only=1 Oestrogen and progesterone=2 
4 E If previous or current:  Duration of HRT treatment 
4 F Hysterectomy 
Yes=1, No=2 
 
















5. Medical history 
5 A Hypertension 
Yes=1, No=2 
 
5 B If yes: on diuretic? 
Yes=1, No=2 
If yes, type and dose 




5 D Diabetes 
Yes=1, No=2 
5 E If diabetes, insulin dependant? 
Yes=1, No=2 
5 F Oral antihypoglycemics 
 
 
5 G Neurological disorders: Yes=1, No=2  
5 G Psychological disorders:  Yes=1, No=2 






6. Surgical history 
6 A Hysterectomy Yes=1, No=2  
6 B If yes Abdominal=1 Vaginal=2 
6 C Anterior vaginal repair 
Yes=1, No=2 
If yes, details 
 
 
6 D Posterior vaginal repair 
Yes=1, No=2 
If yes, details 
 
6 E Stress in continence surgery 
Yes=1, No=2 
If yes, details 
 
6 G Cystoscopy 
Yes=1, No=2 
If yes, details 
 



















7. History of OAB 
7 A 
 
7 A 1 
 
7 A 2 
 
7 A 3 
 
7 A 4 
 
7 A 5 
 
7 A 6 
 
7 A 7 
 













(straining, post micturation dribbling, incomplete emptying) 
Bladder pain 
7B Duration  of symptoms 
 
7C Was urodynamic studies performed 
Yes=1, No=2 
 
7D If yes, was OAB demonstrated? 
Yes=1, No=2 
7 E  
 
7 E 1 
 
7 E 2 
 
7 E  3 
 
7 E  4 
 
7 E  5 
 
7  E 6 
 
7  E  7 










Stress in continence 
 
Voiding dysfunction 
(straining, post micturation dribbling, incomplete emptying) 
Bladder pain 
 
8. Non pharmacological management 
 
8 A Pelvic floor exercises: 
8 A 1 Date initiated  
 
8 A 2 Date stopped 
8 A 3 Duration of exercises performed  
8 A 4 Improvement documented 
Yes=1, No=2 
 














8 B 1 Date initiated  
8 B 2 Date stopped 
8 B 3 Duration of training  
8 B 4 Improvement documented 
Yes=1, No=2 




9 Pharmacological treatment 
9A1 Oxybutynin : 
Previous=1, current=2, never=3 
 
9A 2 Duration of use 
9A 3 Maximum dose used 
9A 4 If stopped:  Final Reason stopped 
No improvement=1, Side effects=2, Both=3 





9A 5 Other : 
 
 
10. Acupuncture History 
10  A Previous acupuncture 
Yes=1, No=2 
 
 10 B If yes, specify 
 
11.  Urine dipstic 
 Normal 
Yes=1, No=2 






























Appendix 2:  King’s Health Questionnaire 
 
KING’S HEALTH QUESTIONNAIRE 
 
Study number  
  




How would you describe your health at present? 
 















How much do you think your bladder problem affects your life? 
 















































Please turn the page. 
We would like to know what your bladder problems are and how much 
they affect you.  From the list below, choose ONLY THOSE PROBLEMS 




How much do they affect you? 
 
To choose please tick   
 
A little Moderately A lot 
FREQUENCY: going to the toilet to 
often. 
   
NOCTURIA: getting up at night to 
pass urine. 
   
URGENCY: a strong and difficult to 
control desire to pass urine 
   
URGE INCONTINENCE: urinary 
leakage associated with a strong 
desire to pass urine 
   
STRESS INCONTINENCE:  urinary 
leakage with physical activity          
eg coughing, sneezing, running 
   
NOCTURNAL ENURESIS:  wetting the 
bed at night 
   
INTERCOURSE INCONTINENCE:  urinary 
leakage with sexual incontinence 
   
FREQUENT WATERWORKS INFECTION: 
 
   
BLADDER PAIN: 
 
   
Difficulty PASSING URINE: 
 
   
OTHER SPECIFY: 
 
























Below are some daily activities that can be affected by your bladder problems. 
How much does your bladder problem affect you? 
We would like you to answer every question.  Simply tick the circle that applies to you. 
 
 
  Not at 
all 
Slightly Moderately A lot 
ROLE LIMITATIONS 
To what extent does your 
bladder problem affect your 
household tasks (eg cleaning, 
shopping, etc) 
     
Does your bladder problem 
affect your job or your normal 
daily activities outside the 
home? 
     
PHYSICAL / SOCIAL LIMITATIONS 
Does your bladder problem 
affect your physical activities 
(eg going for a walk, run, sport, 
gym, etc) 
     
Does your bladder problem 
affect your ability to travel? 
 
     
Does your bladder problem limit 
your social life? 
     
Does your bladder problem limit 
your ability to see/visit friends? 
     
PERSONAL RELATIONSHIPS Not 
appli-
cable 
Does your bladder problem 
affect your relationship with 
your partner? 
     
Does your bladder problem 
affect your sex life? 
     
Does your bladder problem 
affect your family life? 
     
 
Office Use 



















 Not at all Slightly Moderately A lot 
EMOTIONS 
Does your bladder problem 
make you feel depressed? 
    
Does your bladder problem 
make you feel anxious or 
nervous? 
    
Does your bladder problem 
make you feel bad about 
yourself? 
    









Does your bladder problem 
affect your sleep? 
    
Do you feel worn out / tired? 
 
    
Do you do any of the 
following? 


















Wear pads to keep dry? 
 
    
Be careful how much fluid you 
drink? 
    
Change your underclothes 
when they get wet? 
    
Worry in case you smell? 
 
    
Get embarrassed because of 
your bladder problem? 
    
 
Office Use 
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Appendix 4:  Consent in English 
  
University of Cape Town         
  
   
Dr Steven Jeffery 
Dr Marinus Cloete 
Department of Gynaecology 
Faculty of Health Sciences 
University of Cape Town 






Acupuncture in women with overactive bladder syndrome 
 
INFORMED CONSENT and INFORMATION FORM  
 
Dear Patient  
 
My name is _______________________  
 
I wish to invite you to participate in a study that aims to find out how good acupuncture is in helping to 
treat Overactive bladder (OAB). We hope that this will help us to look better after people living with 
OAB, like you, in the future. The study is being run by the department of Gynaecology at the 
University of Cape Town and will be conducted at the Continence Clinic at Groote Schuur Hospital. Dr 
Steven Jeffery is the Principal Investigator and Dr Marinus Cloete is the Lead Investigator.  
 
OAB is the sudden, intense desire to urinate and can be accompanied by unwanted urine leakage 
(referred to as "wetting accidents"). This happens because the bladder muscle squeezes too often or 
when you don’t want it to. A person may be aware of the sensation to urinate but will be unable to stop 
leakage before reaching the toilet. OAB is also usually associated with wanting to urinate more than 
eight times in a day or twice a night. 
 
We ask you to join in this study because we want to find out more about how to treat people with OAB. 
We as doctors can help patients with OAB to learn to control their bladders and we can prescribe 
medication to take. For most patients these treatments work, but for some it does not. So what is there 
more to do if you feel the treatment is not working? Doctors in America and in Europe have found that 
acupuncture can also work for OAB. We want to see if it will work for our patients for whom other 
treatments did not work. 
 
Acupuncture is an ancient system of healing developed over thousands of years as part of the 
traditional medicine of China. The aim of the treatment is to restore the balance of energy in the body. 
This is done through the painless application of fine needles into strategic points on the body. Inserting 
these very fine needles just into the skin is very safe. 
Upon insertion, you may feel a slight sting. Once the needle is inserted, there should be no pain. You 
should feel comfortable during the treatment. Some people, but they are very few, feel dizzy and 
nauseous. We will stop the treatment immediately if you wish so. 
You will receive four acupuncture treatments every week for four weeks.  Each time seven needles will 
be inserted into your skin; two on your knees, two on your thighs, two on your lower back and one 
under your navel. Every time new needles will be used. A treatment lasts twenty minutes. The medical 
staff inserting the needles is trained to do so. Sometimes during the study we will ask you to keep track 
of your wetting accidents and other bladder problems by writing them down in a diary. 
 
It is very important that you come back for your follow-up appointments so that we can see if the 














three months after the treatment. Each time we will give you a paper with a few questions written on it 
that you must tick. This will take about 10 minutes to complete.  
 
All the information that you give to us will be confidential. Your name will not be on the information 
and the information will not be copied into your clinic notes. All the information will be locked up.  
 
It is possible that you might not benefit from acupuncture at all. We can not guarantee any 
improvement. 
 
If you are still taking medication for OAB you must continue to take this during the treatment with 
acupuncture. We always recommend patients to continue with the bladder training. 
 
This study is not funded and there will be no reimbursement for travelling to the clinic. 
 
This study was approved by the Research Ethics Committee of the University of Cape Town. Their job 
is to ensure your safety and protect you during the study.  
 
The University of Cape Town (UCT) undertakes that in the event of you suffering any significant 
deterioration in health or well being that is caused in your participation in the study it will provide 
immediate medical care. Any trial related injuries are covered by UCT’s insurance. 
 
The decision to participate is entirely your own.  
 
IF YOU DECIDE NOT TO PARTICIPATE, YOUR TREATMENT WILL NOT BE 
DISADVANTAGED IN ANY WAY. In addition, at any point during the study you are free to 
withdraw without telling us why.  
 
Since this is a research study, the results will not be made available to the participants. When the 
results of the study become available, names of the participating patients will not be included.   
 
Do you have any questions? During the study you may contact either the Research Ethics Committee 
(021 406 6492) or Dr Marinus Cloete (0824957831) if you have further questions.   
 
Consent to participate in the study: 
 
I have read the above / the above has been read to me. I have had the opportunity to discuss the study 




I consent to take part in this study:  
 
Name of person consenting     __________________  
  
Signature/ fingerprint              __________________  
 
Date                                            __________________  
  
Name of person taking consent       __________________  
 
Signature                                              __________________  
 
Date                                                      __________________  
 
Name of Witness        __________________ 
 
Signature                                                __________________ 
 

















Appendix 5:  Consent in Afrikaans 
  
Universiteit van Kaapstad         
  
   
Dr Steven Jeffery 
Dr Marinus Cloete 
Departement van Ginekologie 
Fakulteit van Gesondheids Wetenskappe 
Universiteit van Kaapstad 





Akupunktuur in vrouens met ooraktiewe blaas sindroom 
 




Ek is _____________________________ 
 
Ek wil u uitnooi om deel te neem in ‘n navorsings projek waarmee ons wil uitvind hoe goed is 
akupunktuur in die behandeling van ooraktiewe blaas (OAB).  Ons hoop dat dit ons sal help om in die 
toekoms beter te kyk na pasiente met OAB. Die projek word gedoen deur die departement van 
Ginekologie van Universiteteit van Kaapstad by die Kontinensie Kliniek van Groote Schuur Hospitaal. 
Dr Stephen Jeffery is die Prinsipale Navorser en Dr Marinus Cloete is die Hoof Navorser. 
 
OAB is die skielike, intense behoete om te urineer en kan lei tot ongewenste urine lek (verwys na as 
“nat ongelukkies”). Dit gebeur omdat die blaas spier the veel saamtrek of saamtrek wanneer jy dit nie 
wil he nie.  ‘n Persoon mag bewus wees van die behoefte om te urineer maar sal nie urine lek kan keer 
voor hulle by die toilet uitkom nie. OAB is ook gewoonlik geassosieer met die behoefte om meer as agt 
keep op ‘n dag te urineer en meer as twee keer per nag. 
 
Ons vra u om deel te neem aan die navorsings projek sodat ons meer kan leer oor hoe om mense met 
OAB te behandel. As dokters kan ons mense probeer help om hulle blase te beheer en medikasie voor 
te skryf, maar dit werk nie altyd nie. Dokters in Amerika en Europa het uitgevind dat akupunktuur help 
vir OAB. Ons wil kyk of dit vir ons patiente ook gaan help sodat ons hulle beter kan behandel. 
 
Akupunktuur is ‘n eeu oue sisteem van heeling wat ontwikkel is oor duisende jare as deel van 
tradisionele Chinese medisyne. Die doel van die behandeling is om die energie balans in die liggaam te 
herstel, deur die pynlose plaasing van fyn naaldjies op strategiese plekke in die liggaam. Dit is baie 
veilig om hierdie fyn naaldjies net onder die vel in te druk. Wanneer dit ingedruk word kan u ‘n ligte 
prik voel, maar wanneer die naaldjie in is sal u geen pyn voel nie. U moet gemaklik voel gedurende die 
behandeling. Party mense, hulle is by verre in die minderheid, voel bietjie duislig en naar. 
U sal vier akupunktuur behandelings oor ‘n tydperk van vier weke ondergaan. Met elke behandeling sal 
sewe naaldjies onder u vel geplaas word; twee op u knee, twee op u bobene, twee op u laer rug en een 
onder u naeltjie. Met elke behandeling word nuwe naalde gebruik. ‘n Behandeling duur twintig minute. 
Al die mediese personeel wat die naaldjies inplaas is opgelei daarin.  
 
Op seker intervalle gedurende die projek sal ons u vra om tred te hou van u ongelukkies en ander blaas 
porbleme deur dit neer te skryf in ‘n boekie. 
 
Dit is baie belangrik dat u sal terugkom vir u opvolg besoeke sodat ons kan sien of die akupuntuur u 
gehelp het of nie. Ons sal u vra om drie keer terug te kom:  twee weke, een maand en drie maande na 
die behandeling. Ons sal u elke keer vra om ‘n vraelys uit te vul deur antwoorde te merk. Dit sal 















Die projek sal gemoniteer word deur die Navorsings Raad van die Universiteit van Kaapstad. Hulle is 
daar om u veiligheid te verseker gedurende die projek.  Die Universiteit van Kaapstad (UK) onderneem 
om mediese behandeling te voorsien sou u gesondheid aansienlik deur die studie geaffekteer word. 






Die besluit om deel te neem moet geheel en al u eie wees. 
 
SOU U BESLUIT OM NIE DEEL TE NEEM NIE, SAL U BEHANDELING IN GEEN WYSE 
DAAR ONDER LEI NIE. Verder mag U enige tyd gedurende die projek besluit om te ontrek sonder 
om te se hoekom. 
 
Aangesien dit ‘n navorsings projek is kan ons nie vir u die uitslae van die vraelyste gee nie. Die 
antwoorde op die vraelyste bly bewaar deur die Hoof Navorser en u naam sal nooit daarop verskyn nie 
nie.  
 
Het u enige vra? Gedurende die projek is u welkom om die Navorsings Raad (021-4066492) of Dr 
Marinus Cloete (0824957831) te skakel met verder vrae. 
 
Toestemming om deel te neem in ‘n navorsings projek: 
 
Ek het bogenoemde gelees/ dit is aan my voorgelees. Ek het die geleentheid gehad om dit te bespreek 
met Dr__________________________ en ek kon vrae vra. 
 
Ek gee toestemming om deel te neem aan die navorsings projek:  
 
Naam van persoon wat toestemming gee     __________________  
  
Handtekening/ Vingerafdruk            __________________  
 




Naam van persoon wat toestemming neem       __________________  
 
Handtekening                                                      __________________  
 




Naam van Getuie                                    __________________ 
 
Handtekening                                                       __________________ 
 
Datum                                                                    ___________________ 





















Appendix 6:  Consent in Xhosa  
 
        uGqirha Steven Jeffery  
        uGqirha Marinus Cloete 
        Kwicandelo Lwezabafazi 
        KwiDyunivesi yaseKapa 
        Isitalato yi Anzio 
        eObservetory 
        7925 
Unyango ngeenaliti kubafazi abanezinyi ezingalawulekiyo . 
 
Isivumelwaqno nephepha lwencukanca. 
 
Sigulane esithandekayo  
 
Igama lam ngu……………………………………………………………………… 
 
Ndinqwenela ukukumema ukuba uthathe inxaxheba kwizifundo ngokufuna ukwazi ukuba. 
Unyango lwenaliti lubanceda njani abantu abanezinyi ezingalawulekiyo .Siyathemba ukuba ekwenzeni 
kwethu oluphando luyokusinceda ekuphandeni ngokungcono abantu abaphila nalenqxaki yesinyi 
esingalawulekiyo ekuhambeni kwexesha. Izifundo ezi ziqhutywa licandelo lwicandelo Lezabafazi kwi 
Dyunivesi yase Kapa kwaye ziyakubanjelwa kwiklinik kwisibhedlele sase Groote Schuur , uQqirha 
Steven Jeffery uyi nqununu aze u Marinus Cloete yena abeyinhloko koluphando . 
 
Isinyi esingalawulekiyo kuikufuna ukuchama ngesaphume kwaye ingade uzichamele nokuzichamela. 
Kwenzaka okokuba izihlunu zesinyi ziyacunduselana ngokukhawuleza. Uye uzive ukuba ufuna 
ukuchama kodwa ungakwazi ukulawula umchamo xana uphumayo phambi kokuba ufike endlwini 
wangasese . Xana unessinyi esingalawulekiyo senza nakanjalo ukuba ufune ukuchama kakhulu 
amaxesha asibhozo ngemini okanye kabini ngobusuku. 
 
Siyakucela ukuba uzokuthatha inxaxheba kwezizifundo kuba sifuna ukufumanisa ngokuphangaleleyo 
ukuba sinfgabanyanga kanjani abantu abanezinyi ezingalawulekiyo. Thina singoogqirha singabanceda 
abantu abanalenqxaki ukuba bafunde ukulawula izinyi zabo kwaye siyabanika namayeza abawathathe 
kodwa oku akusoloko kusebenza . 
Oogqirha bas melika(America)naseYurophu (Europe) bafumanise ukuba unyango lwenaliti luyanceda 
nalo kwingxaki zesiinyi esingangalawulekiyo. Sifuna ukubona ulunyango luzokusebenza na 
kwizigulana zethu ukwenzela ukuba sibenako ukubanika unyango olunqcono. 
 
Unyango ngenaliti luhlobo lakudala kakhulu olunyango siluthathe etshayina(China). Injongo 
zolunyangpo ku,kunqcna iminyango idlamkile ngokufaka inaliti kwindawo. Ezithile apha emzimbeni 
.Ukufakwa kwe naliti esikhumbeni somzimba akunabungozi kwaphela. Xa ezinaliti zifakwa 
emzimbeni uzokuva nje xa uhlatywayo xa sele ingene inaliti esikhumbeni awuva kwanto uzoba 
uzizolele nje .Abanye abanye abanye abantu baye bazive benesiyezi kwaye nathi bazokugabha kodwa 
babambalwa kakhulu abobantu. Uzakufumana unyango lwenaliti amaxesha amane (four)qho ngeveki 
iiveki ezine(four).Qho ngexesha lonyango ufumana iinaliti ezisixhenxe esikhumbeni okanye elofeleni 
lomzimba (skin)ziyakuba mbini emadolweni (knees)zibembini emathangeni(thighs)zibembini 
ngasemva esinqeni(back) ibenye phantsi kombono(navel).Ngawo onke amaxesha kusetyenziswa inaliti 
ezintsha. Unyango olu luthatha imizuzu engamashumi amabini (20 minits). Bonke abasebenzi 
abasebenza kolunyango baluqeqeqqshelwe. 
 
Kuzakubakho amaxesha esizakuthi sikucele ukuba uqwalasele ingozi zokuzimanzisa kwakunye 
nezinye ingxaki othi uzifumane zesinyi ngokuthi uzibhale phantsi encwadini yakho. 
 
 
Isivumelwano sokuthatha inxaxheba kwezisifundo: 
 
Ndifunde okanye ndifundelwe ,kwaye ndinethuba lokuxoxa no  















Ndiyavuma ukuthatha inxaxheba kwizifundo : 
Igama lomntu ovumayo…………………………………………… 
Sayina okanye beka ubhontsi……………………………………… 
Umhla….......................................... 
 
Igama lomntu othatha isivumelwano 
……………………………………………………………………… 
Sayina ……………………………………………………………… 
Umhla……………………………… 
 
Igama lenqina………………………………………………………. 
Sayina………………………………………………………………. 
Umhla………………………………  
 
 
 
 
 
 
 
 
 
 
 
